Moderna : Une année 2024 qui pose les fondations de 2025 et 2026
>Une année 2024 qui donnera la tendance de 2025 - Nous avions le plaisir d’avoir en RS Stéphane Bancel, CEO de Moderna. Ce rendez-vous investisseurs a permis notamment de remettre en exergue les prochaines étapes de la société : 1/cliniques, 2/réglementaires et 3/commerciales. Au niveau des vaccins respiratoires, nous retenons tout d’abord la confirmation de lancer 4 nouveaux ARNm d’ici à fin 2025 : 1/ Virus Syncitial Respiratoire (RSV), 2/ grippe saisonnière, 3...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.